A new Ebola drug grown from special tobacco plants has been shown to cure monkeys that were already displaying signs of infection by the viral hemorrhagic fever, the Los Angeles Times reported on Wednesday.
Other Ebola countermeasures have been shown to work on infected animals before they start displaying symptoms of the highly virulent and lethal disease. However, this is the first time a drug has demonstrated any effectiveness after signs of the virus have manifested. That is regarded as a crucial capability in the event of a real-life disease epidemic, according to virologist Gene Olinger, who works at the Army Medical Research Institute of Infectious Diseases at Fort Detrick, Md.
“We’ve pushed the opportunity to treat people to the point where they walk in and say, ‘I have a fever,’” said Olinger, co-author of a report on the new Ebola drug published by the Science Translational Medicine journal on Wednesday. “A lot of folks in the field would have thought protecting an animal at the time of fever and viremia is too late to have a clinical benefit.”
Ebola is one of the most deadly and contagious diseases known to exist in nature. The lack of adequate vaccines and antidotes for the disease have made it a serious worry for biodefense specialists concerned about its possible applications as a biological weapon.
In the recent study, seven infected rhesus monkeys were administered the experimental treatment MB-003 through their veins once every three days. Three of the monkeys did not die, resulting in a statistically notable success rate of 43 percent.
Fort Detrick scientist and lead study author James Pettitt said it is probable that in a real-life outbreak, the drug would be administered at a higher dosage and with greater frequency.
“We think we’ll get better results,” the researcher said.
Growing the drug from specially developed tobacco leaves is not only less costly than conventional cell-based methods, but also allows for large batches of the drug to be produced on fairly short, weeklong schedules, according to the Times article.
Olinger said further measures will be taken to improve MB-003 by adding to it more Ebola antibodies that were discovered by a different group of researchers.
What We're Following See More »
Trump, in a statement: “Based on the fact that the Democratic nominating process is totally rigged and Crooked Hillary Clinton and Deborah Wasserman Schultz will not allow Bernie Sanders to win, and now that I am the presumptive Republican nominee, it seems inappropriate that I would debate the second place finisher. ... I will wait to debate the first place finisher in the Democratic Party, probably Crooked Hillary Clinton, or whoever it may be.”
"It's about time for unity," said UAW President Dennis Williams. "We're endorsing Hillary Clinton. She's gotten 3 million more votes than Bernie, a million more votes than Donald Trump. She's our nominee." He called Sanders "a great friend of the UAW" while saying Trump "does not support the economic security of UAW families." Some 28 percent of UAW members indicated their support for Trump in an internal survey.
"Donald Trump on Thursday reached the number of delegates needed to clinch the Republican nomination for president, completing an unlikely rise that has upended the political landscape and sets the stage for a bitter fall campaign. Trump was put over the top in the Associated Press delegate count by a small number of the party's unbound delegates who told the AP they would support him at the convention."
"Clinton and Bernie Sanders "are now devoting additional money to television advertising. A day after Sanders announced a new ad buy of less than $2 million in the state, Clinton announced her own television campaign. Ads featuring actor Morgan Freeman as well as labor leader and civil rights activist Dolores Huerta will air beginning on Fridayin Fresno, Sacramento, and Los Angeles media markets. Some ads will also target Latino voters and Asian American voters. The total value of the buy is about six figures according to the Clinton campaign." Meanwhile, a new poll shows Sanders within the margin of error, trailing Clinton 44%-46%.